Ming Duan1, Lei Cao1, Lei Gao1, Jianfeng Gong1, Yi Li2, Weiming Zhu3. 1. Jinling Hospital Research Institute General Surgery, Nanjing University, School of Medicine, No. 305 East Zhongshan Road, Nanjing, 210002, China. 2. Jinling Hospital Research Institute General Surgery, Nanjing University, School of Medicine, No. 305 East Zhongshan Road, Nanjing, 210002, China. liyi.jlh@hotmail.com. 3. Jinling Hospital Research Institute General Surgery, Nanjing University, School of Medicine, No. 305 East Zhongshan Road, Nanjing, 210002, China. juwiming@nju.edu.cn.
Abstract
BACKGROUND: The rate of postoperative ileus following stoma closure is high in patients with Crohn's disease and temporary enterostomy. AIMS: To evaluate the effect of chyme reinfusion on postoperative outcomes including ileus in these patients. METHODS:Patients were screened from January 2012 to December 2017 and divided into chyme reinfusion group (n = 33) and non-chyme reinfusion group (n = 84). The following 30-day postoperative outcomes were evaluated. Univariate and multivariate analyses and propensity score matching were performed to identify risk factors for these postoperative outcomes. RESULTS: The incidence of postoperative ileus was significantly lower in the chyme reinfusion than in non-chyme reinfusion group, which had been confirmed by the results after matching (3/26 vs 11/26, p = 0.012). The rate of postoperative diarrhea was significantly lower in the chyme reinfusion group compared with non-chyme reinfusion group, whereas the difference was not significant after matching (2/26 vs 6/26, p = 0.191). Additionally, the postoperative length of stay was significantly shorter in the chyme reinfusion than in non-chyme reinfusion group before and after propensity score matching. In the multivariate analysis, chyme reinfusion was an independent protective factor for postoperative ileus (odds ratio 0.218; 95% confidence interval 0.05-0.95; p = 0.042) and for postoperative length of stay (coefficient - 0.191; 95% confidence interval - 0.350 to - 0.032, p = 0.019). CONCLUSIONS:Chyme reinfusion was associated with lower rate of postoperative ileus and shorter length of stay following stoma closure in Crohn's patients with temporary ileostomy. Further randomized clinical trial between patients with or without chyme reinfusion was needed to confirm these conclusions.
RCT Entities:
BACKGROUND: The rate of postoperative ileus following stoma closure is high in patients with Crohn's disease and temporary enterostomy. AIMS: To evaluate the effect of chyme reinfusion on postoperative outcomes including ileus in these patients. METHODS:Patients were screened from January 2012 to December 2017 and divided into chyme reinfusion group (n = 33) and non-chyme reinfusion group (n = 84). The following 30-day postoperative outcomes were evaluated. Univariate and multivariate analyses and propensity score matching were performed to identify risk factors for these postoperative outcomes. RESULTS: The incidence of postoperative ileus was significantly lower in the chyme reinfusion than in non-chyme reinfusion group, which had been confirmed by the results after matching (3/26 vs 11/26, p = 0.012). The rate of postoperative diarrhea was significantly lower in the chyme reinfusion group compared with non-chyme reinfusion group, whereas the difference was not significant after matching (2/26 vs 6/26, p = 0.191). Additionally, the postoperative length of stay was significantly shorter in the chyme reinfusion than in non-chyme reinfusion group before and after propensity score matching. In the multivariate analysis, chyme reinfusion was an independent protective factor for postoperative ileus (odds ratio 0.218; 95% confidence interval 0.05-0.95; p = 0.042) and for postoperative length of stay (coefficient - 0.191; 95% confidence interval - 0.350 to - 0.032, p = 0.019). CONCLUSIONS: Chyme reinfusion was associated with lower rate of postoperative ileus and shorter length of stay following stoma closure in Crohn's patients with temporary ileostomy. Further randomized clinical trial between patients with or without chyme reinfusion was needed to confirm these conclusions.
Authors: Leith Williams; Matthew J Armstrong; Matthew Armstrong; Paul Finan; Peter Sagar; Dermot Burke Journal: Gut Date: 2007-01-17 Impact factor: 23.059
Authors: Wolfgang B Gaertner; Robert D Madoff; Anders Mellgren; Mary R Kwaan; Genevieve B Melton Journal: Am J Surg Date: 2015-06-04 Impact factor: 2.565
Authors: Thorsten Löffler; Inga Rossion; Thomas Bruckner; Markus K Diener; Moritz Koch; Moritz von Frankenberg; Julius Pochhammer; Oliver Thomusch; Thomas Kijak; Thomas Simon; André L Mihaljevic; Matthias Krüger; Erwin Stein; Gerald Prechtl; René Hodina; Walter Michal; Roland Strunk; Karl Henkel; Jörg Bunse; Gregor Jaschke; Dirk Politt; Hans Peter Heistermann; Mathis Fußer; Claas Lange; Achim Stamm; Andreas Vosschulte; Ralf Holzer; Lars Ivo Partecke; Emanuel Burdzik; Hubert M Hug; Steffen P Luntz; Meinhard Kieser; Markus W Büchler; Jürgen Weitz Journal: Ann Surg Date: 2012-11 Impact factor: 12.969
Authors: J Ocaña; J C García-Pérez; M Labalde-Martínez; G Rodríguez-Velasco; I Moreno; A Vivas; I Clemente-Esteban; A Ballestero; P Abadía; E Ferrero; J M Fernández-Cebrián; J Die Journal: Tech Coloproctol Date: 2022-05-21 Impact factor: 3.699
Authors: Chen Liu; Emma Ludlow; Robert B Davidson; John B Davidson; Kaitlyn S Chu; Gregory O'Grady; Ian P Bissett Journal: Dis Colon Rectum Date: 2021-11-01 Impact factor: 4.412